title: [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment].
abstract: OBJECTIVE
  This study aims to compare the measurements using biochemical markers of bone turnover and bone mineral density (BMD) in the assessment of the efficiency of osteoporosis treatment.
  
  
  METHODS
  Between March 2006 and December 2008, 166 patients with osteoporosis in our clinic were included. Patients who were out of contact due to death or other reasons during follow-up were excluded. We compared the measurements of urinary biochemical markers of bone turnover using cross-linked N-telopeptide (Ntx) values and BMD in 60 patients (49 females, 11 males; mean age: 65.7 years; range: 42 to 87 years) with osteoporosis who were treatment-naive and completed study.
  
  
  RESULTS
  Twenty-nine (48.3%) of the patients received surgical treatment, while 31 (51.7%) received conservative therapy. Urine NTx values of the patients decreased 38.82% at three months; 51.99% at six months and 66.41% at 12 months. Lumbar vertebra BMD increased by 20.7% and femur neck BMD increased by 11.9% at the end of the first year.
  
  
  CONCLUSIONS
  Urine NTx values respond to osteoporosis treatment faster than BMD measurements; thereby it may be suitable to use this parameter for the monitorization of the treatment efficiency.
authors.affiliation: Gazi Üniversitesi Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, Ankara, Türkiye. baybarsataoglu@gazi.edu.tr
authors.forename: M Baybars
authors.initials: MB
authors.lastname: Ataoğlu
authors.forename: O Şahap
authors.initials: OŞ
authors.lastname: Atik
authors.forename: Orkun
authors.initials: O
authors.lastname: Gül
authors.forename: Baran
authors.initials: B
authors.lastname: Sarıkaya
authors.forename: Gökay
authors.initials: G
authors.lastname: Görmeli
authors.forename: Burak Yağmur
authors.initials: BY
authors.lastname: Öztürk
authors.forename: Barış
authors.initials: B
authors.lastname: Özgürol
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism*; D024042:Collagen Type I / Q000652:urine; D005260:Female; D005272:Femur Neck / Q000000981:diagnostic imaging; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000503:physiopathology* / Q000628:therapy / Q000652:urine; D010455:Peptides / Q000652:urine; D011237:Predictive Value of Tests; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide